Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression

Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression

Sep 22, 2010
Source URL: https://qa1.novartis.us/news/media-releases/novartis-gains-fda-approval-gilenyatm-novel-first-line-multiple-sclerosis-treatment-shown-significantly-reduce-relapses-and-delay-disability-progression-0

List of links present in page
  1. https://qa1.novartis.us/news/media-releases/novartis-gains-fda-approval-gilenyatm-novel-first-line-multiple-sclerosis-treatment-shown-significantly-reduce-relapses-and-delay-disability-progression-0